Too Much of a Good Thing? Excess Intake of Vitamins and Minerals

  • Robin B. Kanarek
  • Robin Marks-Kaufman


The past 30 years have witnessed a striking escalation in the average American’s concern with nutrition and health. One of the most obvious signs of this concern is the zeal with which 50 to 60 million Americans each day dutifully swallow pills containing lavish allotments of vitamins and minerals. Believing that vitamin and mineral supplements will prevent a variety of diseases from the common cold to arthritis and cancer, delay the aging process, alleviate feelings of fatigue, and generally improve psychological well-being, these individuals are stimulating the development of a multibillion dollar business. Sales of vitamins, either as single nutrients or multinutrient supplements, now average over 2 billion dollars a year.


Attention Deficit Hyperactivity Disorder Sensory Neuropathy Premenstrual Syndrome Dietary Allowance Vitamin Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albin, R. L., J. W. Albers, H. S. Greenberg, J. B. Townsend, R. B. Lynn, J. M. Burke, and A. G. Alessi. 1987. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 37: 1729–1732.Google Scholar
  2. Alhadeff, L., C. T. Gualitieri, and M. Lipton. 1984. Toxic effects of water-soluble vitamins. Nutrition Reviews 42: 33–40.CrossRefGoogle Scholar
  3. American Psychiatric Association. 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev. Washington, D.C.: American Psychiatric Association.Google Scholar
  4. Arnold, L. E., J. Christopher, R. D. Huestis, and D. J. Smeltzer. 1978. Megavitamins for minimal brain dysfunction. Journal of the American Medical Association 240: 2642–2643.CrossRefGoogle Scholar
  5. Arroyave, G. 1988. Risks and abuses of megadoses of vitamins. Food and Nutrition Bulletin 10: 21–25.Google Scholar
  6. Ashby, W. R., G. H. Collings, and M. Bassett. 1960. The effects of nicotinamide and placebo on the chronic schizophrenic. Journal of Mental Science 106: 1555–1559.Google Scholar
  7. Ban, T. A. 1981. Megavitamin therapy in schizophrenia. In Nutrition and Behavior, ed. S. A. Miller, pp. 247–253. Philadelphia: Frankl in Institute.Google Scholar
  8. Barlow, P. J., P. E. Sylvester, and J. W. T. Dickerson. 1981. Hair trace metal levels in Down’s syndrome patients. Journal of Mental Deficiency Research 25: 161–168.Google Scholar
  9. Bassler, K. H. 1988. Megavitamin therapy with pyridoxine. International Journal of Vitamin and Nutrition Research 58: 105–118.Google Scholar
  10. Bennett, F. C., S. McClelland, E. A. Kriegsmann, L. B. Andrus, and C. J. Sells. 1983. Vitamin and mineral supplementation in Down’s syndrome. Pediatrics 72: 707–713.Google Scholar
  11. Benton, D. and G. Roberts. 1988. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet 1: 140–143.CrossRefGoogle Scholar
  12. Blair, K. A. 1986. Vitamin supplementation and megadoses. Nurse Practitioner 11: 19–36.CrossRefGoogle Scholar
  13. Braun, J. T., R. A. Franciosi, A. R. Mastri, R. M. Drake, and B. L. O’Neil. 1984. Isotretinoin dysomorphic syndrome. Lancet 1: 506–507.CrossRefGoogle Scholar
  14. Brenner, A. 1982. The effects of megadoses of selected B-complex vitamins on children with hyperkinesis: Controlled studies with long-term follow-up. Journal of Learning Disabilities 15: 258–264.CrossRefGoogle Scholar
  15. Brush M. G. 1988. Vitamin B6 treatment of premenstrual syndrome. In Clinical and Physiological Applications of Vitamin B 6, ed. J. E. Leklem and R. D. Reynolds, pp. 363–379. New York: Alan R. Liss.Google Scholar
  16. Chanowitz, J., G. Ellman, C. Silverstein, G. Zingarelli, and E. Ganger. 1985. Thyroid and vitamin-mineral supplements fail to improve IQs of mentally retarded adults. American Journal of Mental Deficiency 90: 217–219.Google Scholar
  17. Coburn, S. P., W. E. Schaltenbrand, J. D. Mahuren, R. J. Clausman, and D. Townsend. 1983. Effect of megavitamin treatment on mental performance and plasma vitamin B6 concentrations in mentally retarded young adults. American Journal of Clinical Nutrition 38: 352–355.Google Scholar
  18. Coleman, M., G. Steinberg, J. Tippett, H. N. Bagavan, D. B. Coursin, M. Gross, C. Lewis, and L. DeVeau. 1979. A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: A double-blind crossover comparison with methylphenidate. Biological Psychiatry 14: 741–751.Google Scholar
  19. Cott, A. 1972. Megavitamins: The orthomolecular approach to behavioral disor¬ders and learning disabilities. Academic Therapy 7: 245–258.Google Scholar
  20. Denson, R. 1962. Nicotinamide in the treatment of schizophrenia. Diseases of the Nervous System 23: 167–172.Google Scholar
  21. Ellis, N. R. and P. D. Tomporowski. 1983. Vitamin/mineral supplements and intelligence of institutionalized mentally retarded adults. American Journal of Mental Deficiency 88: 211–214.Google Scholar
  22. Ellman, G., C. Silverstein, G. Zingarelli, E. Schafer, and L. Silverstein. 1984. Vitamin-mineral supplement fails to improve IQs of mentally retarded young adults. American Journal of Mental Deficiency 88: 688–691.Google Scholar
  23. Fernhoff, P. M. and E. J. Lammer. 1984. Craniofacial features of isoretinoin embryopathy. Journal of Pediatrics 105: 595–597.CrossRefGoogle Scholar
  24. Graham, R. B. 1990. Physiological Psychology. Belmont, CA: Wadsworth.Google Scholar
  25. Greenbaum, C. H. C. 1970. An evaluation of niacinamide in the treatment of childhood schizophrenia. American Journal of Psychiatry 127: 129–132.Google Scholar
  26. Guthrie, H. A. 1989. Introductory Nutrition. St. Louis, MO: Times Mirror/Mosby.Google Scholar
  27. Harrell, R. F., R. H. Capp, D. R. Davis, J. Peerless, and L. R. Ravitz. 1981. Can nutritional supplements help mentally retarded children? An exploratory study. Proceedings of the National Academy of Sciences 78: 574–578.CrossRefGoogle Scholar
  28. Haslam, R. H. A., J. T. Dalby, and A. W. Rademaker. 1984. Effects of megavi¬tamin therapy on children with attention deficit disorders. Pediatrics 74: 103–111.Google Scholar
  29. Hathcock, J. N., D. G. Hatton, M. Y. Jenkins, J. T. McDonald, P. R. Sundaresan, and W. L. Wilkening. 1990. Evaluation of vitamin A toxicity. American Journal of Clinical Nutrition 52: 183–202.Google Scholar
  30. Hegarty, V. 1988. Decisions in Nutrition. St. Louis, MO: Times Mirror/Mosby.Google Scholar
  31. Hoffer, A. 1962. Niacin Therapy in Psychiatry. Springfield, IL: Charles C. Thomas.Google Scholar
  32. Hoffer, A. 1970. Pellegra and schizophrenia. Psychosomatics 11: 522–525.Google Scholar
  33. Hoffer, A., H. Osmond, M. J. Callbeck, and I. Kahan. 1957. Treatment of schizophrenia with nicotinic acid and nicotinamide. Journal of Clinical and Experimental Psychopathology 18: 131–158.Google Scholar
  34. Justice, P. M., S. Kamath, P. W. Langenberg, H. H. Sandstead, D. B. Milne, and G. F. Smith. 1988. Micronutrients status of children with Down’s syndrome: A comparative study of the effect of megadoses of vitamins with minerals or placebo. Nutrition Research 8: 1251–1258.CrossRefGoogle Scholar
  35. Lipton, M. A., R. B. Mailman, and C. B. Nemeroff. 1979. Vitamins, megavitamin therapy, and the nervous system. In Nutrition and the Brain, vol. 3, ed. R. J. Wurtman and J. J. Wurtman, pp. 183–264. New York: Raven Press.Google Scholar
  36. Lott, I. T., M. Bocian, H. W. Pribram, and M. Leitner. 1984. Fetal hydrocephalus and ear abnormalities associated with maternal use of isoretinoin. Journal of Pediatrics 105: 597–600.CrossRefGoogle Scholar
  37. Matin, M., P. Sylvester, D. Edwards, and J. Dickerson. 1981. Vitamin and zinc status in Down’s syndrome. Journal of Mental Deficiency Research 25: 121–126.Google Scholar
  38. McLaren, D. S. 1982. Excessive nutrient intakes. In Adverse Effects of Foods, ed. E. F. P. Jelliffe and D. B. Jelliffe, pp. 367–387. New York: Plenum.CrossRefGoogle Scholar
  39. Parry, G.J. and D. E. Bredsen. 1985. Sensory neuropathy with low-dose pyridoxine. Neurology 35: 1466–1468.Google Scholar
  40. Pauling, L. 1968. Orthomolecular psychiatry. Science 160: 265–271.CrossRefGoogle Scholar
  41. Pruess, J. B., R. B. Fewell, and F. C. Bennett. 1989. Vitamin therapy and children with Down’s sydrome: A review of the research. Exceptional Children 55: 336–341.Google Scholar
  42. Rimland, B. 1974. An orthomolecular study of psychotic children. Journal of Orthomolecular Psychiatry 3: 371–377.Google Scholar
  43. Rimland, B. 1983. Vitamin/mineral supplementation for mental retardation (letter to the editor). Lancet 2: 744–745.CrossRefGoogle Scholar
  44. Rimland, B., E. Calloway, and P. Dreyfus. 1978. The effect of high doses of vitaman B6 on autistic children: A double-blind crossover study. American Journal of Psychiatry 135: 472–475.Google Scholar
  45. Rosa, F. W. 1983. Teratogenicity of isoretinoin. Lancet 2: 513.CrossRefGoogle Scholar
  46. Schaumburg, H., J. Kaplan, A. Windebank, N. Vick, S. Rasmus, D. Pleasure, and M. J. Brown. 1983. Sensory neuropathy from pyridoxine abuse. New England Journal of Medicine 309: 445–448.CrossRefGoogle Scholar
  47. Smith, G. F., D. Spiker, C. P. Peterson, D. Cicchetti, and P. Justine. 1984. Use of megadoses of vitamins and minerals in Down’s syndrome. Journal of Pediatrics 105: 228–234.CrossRefGoogle Scholar
  48. Spreen, O., D. Tupper, A. Risser, H. Tuokko, and D. Edgell. 1984. Human Developmental Neuropsychology. New York: Oxford University Press.Google Scholar
  49. Stimmel, G. L. 1989. Disorders of infancy and children. In Pharmacotherapy A Pathophysiologic Approach, ed. J. T. Piro, R. L. Talbert, P. E. Hayes, G. C. Yee, and L. M. Posey, pp. 671–677, New York: Elsevier.Google Scholar
  50. Turkel, H. 1975. Medical amelioration of Down’s syndrome incorporating the orthomolecular approach. Journal of Orthomolecular Psychiatry 4: 102–115.Google Scholar
  51. Weathers, C. 1983. Effects of nutritional supplementation on IQ and certain other variables associated with Down’s syndrome. American Journal of Mental Deficiency 88: 214–217.Google Scholar
  52. Zametkin, A. J. 1989. The neurobiology of attention-deficit hyperactivity disorder: a synopsis. Psychiatric Annals 19: 584–586.Google Scholar

Copyright information

© Van Nostrand Reinhold 1991

Authors and Affiliations

  • Robin B. Kanarek
    • 1
  • Robin Marks-Kaufman
    • 1
  1. 1.Tufts UniversityMedfordUSA

Personalised recommendations